- |||||||||| Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Medicaid Insurance Coverage for Treatment of Alopecia Areata with Janus Kinase Inhibitors () - Feb 26, 2025 - Abstract #AAD2025AAD_3529; Dermatologists should also champion policy updates to bridge the large coverage gap for baricitinib between AA and RA treatment. Advocacy efforts are needed to improve Medicaid coverage and ensure equitable access to JAK inhibitors for treating AA.
- |||||||||| Switching between Janus kinase inhibitors for treatment of alopecia areata (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 1)) - Feb 26, 2025 - Abstract #AAD2025AAD_3233;
Switching JAKis may benefit patients with severe alopecia areata who fail initial treatment. Whether this is due to dose effect or JAK specificity requires further study.
- |||||||||| Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Patient Preferences for the Treatment of Alopecia Areata (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 2)) - Feb 21, 2025 - Abstract #AAD2025AAD_2823; Whether this is due to dose effect or JAK specificity requires further study. This study found that, with regard to JAK-inhibitor treatment options in AA, given similar safety profiles, patients prefer higher efficacy and shorter time to initial hair regrowth, regardless of daily or twice daily dosing.
- |||||||||| Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Areata () - Feb 21, 2025 - Abstract #AAD2025AAD_2777; Blinded profiles approximating baricitinib 4mg, ritlecitinib, and deuruxolitinib 8mg were ranked as most and least preferred. Our study demonstrated that, regarding JAK-inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset, regardless of daily or twice daily dosing.
- |||||||||| Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score. () - Feb 21, 2025 - Abstract #AAD2025AAD_2577; Background: For adult patients with severe AA, 3 Janus kinase (JAK) inhibitors are currently approved in the United States: baricitinib (2 mg and 4 mg regimens), ritlecitinib (50 mg regimen), and deuruxolitinib (8 mg regimen). Deuruxolitinib was associated with numerically or statistically greater efficacy when compared to other approved systemic JAK inhibitors for severe AA.
- |||||||||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata (clinicaltrials.gov) - Jul 31, 2024 P3, N=407, Completed, A significantly greater proportion of patients treated with deuruxolitinib 8 mg BID vs placebo reported clinically meaningful improvement in overall HADS score, as well as the HADS-A and HADS-D subscales, from baseline to Week 24. Active, not recruiting --> Completed
- |||||||||| Review, Journal: Novel investigational drugs for alopecia areata and future perspectives. (Pubmed Central) - Jun 7, 2024
The results of landmark phase 3 trials for three JAK inhibitors, baricitinib, ritlecitinib, and deuruxolitinib are discussed...It is uncertain how long patients should remain on JAK inhibitors; discontinuation often leads to relapse. A black-box warning for JAK inhibitors was extrapolated from safety data in a rheumatoid arthritis cohort; recent meta-analyses of JAK inhibitors used in dermatology cohorts do not demonstrate the same risk profile.
- |||||||||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - May 31, 2024 P2/3, N=1000, Enrolling by invitation, A black-box warning for JAK inhibitors was extrapolated from safety data in a rheumatoid arthritis cohort; recent meta-analyses of JAK inhibitors used in dermatology cohorts do not demonstrate the same risk profile. Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
- |||||||||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Apr 4, 2024 P2/3, N=1000, Enrolling by invitation, Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025 Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- |||||||||| Litfulo (ritlecitinib) / Pfizer, deuruxolitinib (CTP-543) / Sun Pharma
Partial Restoration of Scalp Microbiota in Alopecia Areata with JAK Inhibitors () - Nov 6, 2023 - Abstract #ISDS2023ISDS_249; In summary, our study sheds light on alterations in scalp microbiota associated with AA and suggests a potential impact of JAK inhibitors on the skin microbiome in the context of AA treatment. These findings contribute to a better understanding of AA's pathophysiology and may have implications for the development of personalized therapeutic approaches targeting the skin microbiota.
- |||||||||| What () - Jul 3, 2023 - Abstract #WCD2023WCD_5896;
There are multiple new treatments on the horizon for AA. Our review focuses on recent clinical trials for this condition and highlights what is to come as far as new and emerging treatments
- |||||||||| Journal: Overview of alopecia areata for managed care and payer stakeholders in the United States. (Pubmed Central) - May 23, 2023
However, several novel therapies that specifically target the immunopathology of AA have emerged, including Janus kinase (JAK) 1/2 inhibitors such as baricitinib and deuruxolitinib, and the JAK3/tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor ritlecitinib...Pezalla is a paid consultant to Pfizer for market access and payer strategy concerns; Fung, Tran, Bourret, Takiya, Peeples-Lamirande, and Napatalung are employees of Pfizer and hold stock in Pfizer. This article was funded by Pfizer.
|